AstraZeneca (LON:AZN) Stock Crosses Above 200-Day Moving Average – Here’s Why

AstraZeneca PLC (LON:AZN)’s stock price crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of £124.76 and traded as high as £137.04. AstraZeneca shares last traded at £135.91, with a volume of 964,678,625 shares changing hands.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on AZN. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Friday, January 16th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of AstraZeneca from £105 to £110 and gave the stock a “sell” rating in a report on Thursday, January 15th. Berenberg Bank lifted their price objective on shares of AstraZeneca from £142 to £145 and gave the company a “buy” rating in a research report on Tuesday, October 21st. Finally, Jefferies Financial Group restated a “buy” rating and issued a £150 target price on shares of AstraZeneca in a research report on Monday, November 10th. Four research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of £138.

AstraZeneca Price Performance

The business has a fifty day moving average price of £137.60 and a 200 day moving average price of £124.76. The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The company has a market capitalization of £210.69 billion, a price-to-earnings ratio of 22.58, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17.

Insider Buying and Selling

In other AstraZeneca news, insider Nazneen Rahman sold 297 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of £134.96, for a total transaction of £40,083.12. Insiders own 0.14% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.